Finance

Lists
Q3 2026 earnings • released • EPS miss -209.09%
See results
BDTX:NASDAQ
Black Diamond Therapeutics Inc
$1.60
-14.25%
(-0.26) 1D
$1.68
+5.60% (+0.089)
After hours
Closed: Nov 10, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BDTX...
Open
$1.90
High
$1.91
Low
$1.58
Mkt. cap
91.64M
Avg. vol.
778.80K
Volume
1.41M
52-wk high
$4.94
52-wk low
$1.58
EPS
-$0.74
Beta
3.48
Shares outstanding
57.45M
No. of employees
21
Open
$1.90
High
$1.91
Low
$1.58
Mkt. cap
91.64M
Avg. vol.
778.80K
Volume
1.41M
52-wk high
$4.94
52-wk low
$1.58
EPS
-$0.74
Beta
3.48
Shares outstanding
57.45M
No. of employees
21
News stories
From web sources and news partners
About Black Diamond Therapeutics Inc
CEO-
Employees21
Founded2014
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteblackdiamondtherapeutics.com
Analyst ratings
Based on 1 analyst giving stock ratings to BDTX in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for BDTX in the last 3 months
Highest
Current $1.60
$11.00 (+589.66%)
Average
$11.00 (+589.66%)
Lowest
$11.00 (+589.66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
$11.00
+589.7%
11/10/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$11.00
+589.7%
08/06/2026
Maury Raycroft
Jefferies
Buy
Maintained
$10.00
+527%
08/06/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$14.00
+777.7%
08/06/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$8.00
+401.6%
08/06/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$8.00
+401.6%
08/06/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/05/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
-$0.17 / -$0.05
-209.09%miss
Revenue / Est. (USD)
- / 6.25M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.44M
6.30M
7.00M
7.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.54M
3.97M
4.26M
4.66M
Operating expense
10.98M
10.26M
11.26M
12.06M
Total operating expenses
10.98M
10.26M
11.26M
12.06M
Operating income
-10.98M
-10.26M
-11.26M
-12.06M
Other non operating income
1.32M
1.16M
1.20M
1.23M
EBT including unusual items
-8.50M
-15.12M
-9.04M
-9.90M
EBT excluding unusual items
-8.50M
-7.92M
-9.04M
-9.90M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8.50M
-15.12M
-9.04M
-9.90M
Net profit margin
-
-
-
-
Earnings per share
-0.15
-0.14
-0.16
-0.17
Interest and investment income
1.16M
1.18M
1.02M
922.00K
Interest expense
-
-
-
-
Net interest expenses
1.16M
1.18M
1.02M
922.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.89M
-10.20M
-11.23M
-12.03M
Gain or loss from assets sale
-1.00K
-3.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps